• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

增强细胞毒性 T 细胞的抗肿瘤活性:增加 TCR 亲合力的 IGSF4 跨膜结构域。

Potentiating the Antitumor Activity of Cytotoxic T Cells the Transmembrane Domain of IGSF4 That Increases TCR Avidity.

机构信息

School of Life Sciences, Gwangju Institute of Science and Technology (GIST), Gwangju, South Korea.

Immune Synapse and Cell Therapy Research Center, Gwangju Institute of Science and Technology (GIST), Gwangju, South Korea.

出版信息

Front Immunol. 2021 Feb 1;11:591054. doi: 10.3389/fimmu.2020.591054. eCollection 2020.

DOI:10.3389/fimmu.2020.591054
PMID:33597944
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7882689/
Abstract

A robust T-cell response is an important component of sustained antitumor immunity. In this respect, the avidity of TCR in the antigen-targeting of tumors is crucial for the quality of the T-cell response. This study reports that the transmembrane (TM) domain of immunoglobulin superfamily member 4 (IGSF4) binds to the TM of the CD3 ζ-chain through an interaction between His177 and Asp36, which results in IGSF4-CD3 ζ dimers. IGSF4 also forms homo-dimers through the GxxVA motif in the TM domain, thereby constituting large TCR clusters. Overexpression of IGSF4 lacking the extracellular (IG4ΔEXT) domain potentiates the CD8 T cells to release IFN-γ and TNF-α and to kill OVA-B16F10 melanoma cells. In animal models, IG4ΔEXT significantly reduces B16F10 tumor metastasis as well as tumor growth. Collectively, the results indicate that the TM domain of IGSF4 can regulate TCR avidity, and they further demonstrate that TCR avidity regulation is critical for improving the antitumor activity of cytotoxic T cells.

摘要

T 细胞应答的强大是持续抗肿瘤免疫的重要组成部分。在这方面,TCR 在肿瘤抗原靶向中的亲合力对于 T 细胞应答的质量至关重要。本研究报告称,免疫球蛋白超家族成员 4(IGSF4)的跨膜(TM)结构域通过 His177 和 Asp36 之间的相互作用与 CD3 ζ 链的 TM 结合,导致 IGSF4-CD3 ζ 二聚体。IGSF4 还通过 TM 结构域中的 GxxVA 基序形成同源二聚体,从而构成大型 TCR 簇。过表达缺失细胞外(IG4ΔEXT)结构域的 IGSF4 可增强 CD8 T 细胞释放 IFN-γ 和 TNF-α 并杀死 OVA-B16F10 黑色素瘤细胞。在动物模型中,IG4ΔEXT 显著减少 B16F10 肿瘤转移和肿瘤生长。总的来说,这些结果表明 IGSF4 的 TM 结构域可以调节 TCR 亲合力,并且进一步证明 TCR 亲合力调节对于提高细胞毒性 T 细胞的抗肿瘤活性至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/405b/7882689/573e19eb77c0/fimmu-11-591054-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/405b/7882689/825a15b14ffc/fimmu-11-591054-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/405b/7882689/e943cf340fb3/fimmu-11-591054-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/405b/7882689/fd485ec71af2/fimmu-11-591054-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/405b/7882689/36c4a68791fb/fimmu-11-591054-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/405b/7882689/573e19eb77c0/fimmu-11-591054-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/405b/7882689/825a15b14ffc/fimmu-11-591054-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/405b/7882689/e943cf340fb3/fimmu-11-591054-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/405b/7882689/fd485ec71af2/fimmu-11-591054-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/405b/7882689/36c4a68791fb/fimmu-11-591054-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/405b/7882689/573e19eb77c0/fimmu-11-591054-g005.jpg

相似文献

1
Potentiating the Antitumor Activity of Cytotoxic T Cells the Transmembrane Domain of IGSF4 That Increases TCR Avidity.增强细胞毒性 T 细胞的抗肿瘤活性:增加 TCR 亲合力的 IGSF4 跨膜结构域。
Front Immunol. 2021 Feb 1;11:591054. doi: 10.3389/fimmu.2020.591054. eCollection 2020.
2
IGSF4 is a novel TCR ζ-chain-interacting protein that enhances TCR-mediated signaling.IGSF4 是一种新型 TCR ζ 链相互作用蛋白,可增强 TCR 介导的信号转导。
J Exp Med. 2011 Nov 21;208(12):2545-60. doi: 10.1084/jem.20110853. Epub 2011 Nov 14.
3
High-avidity T cells are preferentially tolerized in the tumor microenvironment.高亲合力 T 细胞在肿瘤微环境中优先被耐受。
Cancer Res. 2013 Jan 15;73(2):595-604. doi: 10.1158/0008-5472.CAN-12-1123. Epub 2012 Nov 30.
4
Optimizing T-cell receptor avidity with somatic hypermutation.通过体细胞高频突变优化 T 细胞受体亲和力。
Int J Cancer. 2019 Nov 15;145(10):2816-2826. doi: 10.1002/ijc.32612. Epub 2019 Aug 24.
5
T-cell receptor gene therapy of established tumors in a murine melanoma model.小鼠黑色素瘤模型中已形成肿瘤的T细胞受体基因治疗
J Immunother. 2008 Jan;31(1):1-6. doi: 10.1097/CJI.0b013e31815c193f.
6
T cell receptor transgenic lymphocytes infiltrating murine tumors are not induced to express foxp3.转 T 细胞受体淋巴细胞浸润鼠肿瘤不会诱导其表达 foxp3。
J Hematol Oncol. 2011 Nov 23;4:48. doi: 10.1186/1756-8722-4-48.
7
Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance.Cish在CD8+T细胞中积极沉默TCR信号,以维持肿瘤耐受性。
J Exp Med. 2015 Nov 16;212(12):2095-113. doi: 10.1084/jem.20150304. Epub 2015 Nov 2.
8
The duration of TCR/pMHC interactions regulates CTL effector function and tumor-killing capacity.TCR/pMHC相互作用的持续时间调节CTL效应功能和肿瘤杀伤能力。
Eur J Immunol. 2009 Aug;39(8):2259-69. doi: 10.1002/eji.200939341.
9
Adoptive T Cell Therapy with IL-12-Preconditioned Low-Avidity T Cells Prevents Exhaustion and Results in Enhanced T Cell Activation, Enhanced Tumor Clearance, and Decreased Risk for Autoimmunity.过继性细胞治疗采用 IL-12 预处理低亲和性 T 细胞可预防衰竭并增强 T 细胞激活、增强肿瘤清除、降低自身免疫风险。
J Immunol. 2020 Sep 1;205(5):1449-1460. doi: 10.4049/jimmunol.2000007. Epub 2020 Jul 31.
10
Generation and characterization of HLA-A2 transgenic mice expressing the human TCR 1G4 specific for the HLA-A2 restricted NY-ESO-1 tumor-specific peptide.表达针对 HLA-A2 限制性 NY-ESO-1 肿瘤特异性肽的人 TCR 1G4 的 HLA-A2 转基因小鼠的构建与鉴定。
J Immunother Cancer. 2021 Jun;9(6). doi: 10.1136/jitc-2021-002544.

引用本文的文献

1
A Novel Molecular Classification Method for Glioblastoma Based on Tumor Cell Differentiation Trajectories.一种基于肿瘤细胞分化轨迹的胶质母细胞瘤分子分类新方法。
Stem Cells Int. 2023 Feb 22;2023:2826815. doi: 10.1155/2023/2826815. eCollection 2023.
2
Not Only Immune Escape-The Confusing Role of the TRP Metabolic Pathway in Carcinogenesis.不仅仅是免疫逃逸——瞬时受体电位代谢途径在肿瘤发生中的复杂作用
Cancers (Basel). 2021 May 28;13(11):2667. doi: 10.3390/cancers13112667.

本文引用的文献

1
The Emerging World of TCR-T Cell Trials Against Cancer: A Systematic Review.针对癌症的TCR-T细胞试验的新兴领域:一项系统综述。
Technol Cancer Res Treat. 2019 Jan 1;18:1533033819831068. doi: 10.1177/1533033819831068.
2
Leveraging TCR Affinity in Adoptive Immunotherapy against Shared Tumor/Self-Antigens.利用 TCR 亲和力在针对共享肿瘤/自身抗原的过继免疫治疗中。
Cancer Immunol Res. 2019 Jan;7(1):40-49. doi: 10.1158/2326-6066.CIR-18-0371. Epub 2018 Nov 27.
3
Membrane Ultrastructure and T Cell Activation.膜超微结构与 T 细胞激活。
Front Immunol. 2018 Sep 25;9:2152. doi: 10.3389/fimmu.2018.02152. eCollection 2018.
4
T cell microvilli constitute immunological synaptosomes that carry messages to antigen-presenting cells.T 细胞微绒毛构成免疫突触小体,将信息传递给抗原呈递细胞。
Nat Commun. 2018 Sep 7;9(1):3630. doi: 10.1038/s41467-018-06090-8.
5
Expansion of tumor-infiltrating lymphocytes and their potential for application as adoptive cell transfer therapy in human breast cancer.肿瘤浸润淋巴细胞的扩增及其在人类乳腺癌中作为过继性细胞转移疗法的应用潜力。
Oncotarget. 2017 Dec 6;8(69):113345-113359. doi: 10.18632/oncotarget.23007. eCollection 2017 Dec 26.
6
Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts.CAR T 细胞的临床开发——转化创新治疗理念的挑战与机遇。
EMBO Mol Med. 2017 Sep;9(9):1183-1197. doi: 10.15252/emmm.201607485.
7
Chimeric Antigen Receptors: A Cell and Gene Therapy Perspective.嵌合抗原受体:细胞与基因治疗视角
Mol Ther. 2017 May 3;25(5):1117-1124. doi: 10.1016/j.ymthe.2017.03.034. Epub 2017 Apr 26.
8
Microvilli set the stage for T-cell activation.微绒毛为T细胞激活奠定了基础。
Proc Natl Acad Sci U S A. 2016 Oct 4;113(40):11061-11062. doi: 10.1073/pnas.1613832113. Epub 2016 Sep 23.
9
Three-dimensional localization of T-cell receptors in relation to microvilli using a combination of superresolution microscopies.利用超分辨率显微镜组合技术对T细胞受体与微绒毛进行三维定位
Proc Natl Acad Sci U S A. 2016 Oct 4;113(40):E5916-E5924. doi: 10.1073/pnas.1605399113. Epub 2016 Sep 19.
10
Immunotherapy Expands and Maintains the Function of High-Affinity Tumor-Infiltrating CD8 T Cells In Situ.免疫疗法在原位扩展并维持高亲和力肿瘤浸润性CD8 T细胞的功能。
J Immunol. 2016 Sep 15;197(6):2509-21. doi: 10.4049/jimmunol.1502659. Epub 2016 Aug 8.